BETA three-lens brief
Evidence-based stock research on BETA. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Currently unprofitable on a trailing basis — no P/E multiple available.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Outperforming SPY by 25.8pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Negative free cash flow last quarterly (-$335.47M).
- Reported earnings on 2026-11-03.
BETA closed at $27.72 (-1.32%) as of 2026-11-12. Market cap: $6.51B. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; outperforming SPY by 25.8pp over 30 days.. Concerns: currently unprofitable on a trailing basis — no P/E multiple available.; negative free cash flow last quarterly (-$335.47M).. Last quarter: Revenue $17.67M, net income -$119.12M, free cash flow -$335.47M.
Why three lenses on BETA, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BETA across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/BETA" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BETA brief"></iframe>